Recipharm, the contract development and manufacturing organisation has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.
Recipharm, the contract development and manufacturing organisation (CDMO) has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.
The aptamer-based drug candidate is intended to treat life-threatening condition sepsis, a potentially fatal condition which involves a general inflammatory response, known as systemic inflammatory response syndrome (SIRS), caused by an infection.
Recipharm, which has extensive experience in pharmaceutical formulation, will develop an injectable formulation for the upcoming Phase 1 study.
Anders Högdin, Ph.D., Senior Sales Director at Recipharm, comments: “We are pleased to be able to contribute to the development of Aptahem’s leading drug candidate which has the potential to meet the major medical needs that exist for sepsis patients.
“Recipharm has extensive experience in developing drugs for clinical trials, as well as in commercial manufacturing and we believe that our team’s expertise will be a very valuable asset during this new collaboration.”
The partnership follows the positive results of Apta-1’s exploratory sepsis study with non-human primates (NHP) which provided a greater understanding of the anticoagulant, anti-inflammatory and immunomodulatory effects of the candidate and continued to support its multifunctional potential within its therapeutic area.
Mikael Lindstam, CEO of Aptahem said, “We are extremely pleased to be able to access the strong competence and experience that Recipharm has through this agreement. Choosing a partner to help us progress our drug candidate is a significant milestone. We are now moving at full speed ahead in the development process of Apta-1 and with this cooperation now established I am convinced that we will be able to accelerate further.”
Contact information
Anders Högdin, Senior Sales Director, anders.hogdin@recipharm.com, +46 8 6024 688
Mikael Lindstam, CEO, ml@aptahem.com, +46 766 33 36 99
For media enquiries, please contact Kate Hindhaugh at ramarketing: kate@ramarketingpr.com, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 7,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 7.2 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
About Aptahem
Aptahem AB (Spotlight: APTA) is a biotechnology company that develops aptamer-based drugs for the treatment of life-threatening conditions where coagulation and inflammation interact in the disease process. Apta-1, the company’s leading drug candidate, is an emergency drug that is being developed with the goal of stopping the organ and tissue damage that lead to the very high mortality rate for, among others, patients with sepsis. The company holds patent protection in strategic target markets and conducts active business development work towards future business partners.
For more information on Aptahem and our services, please visit https://aptahem.com/en/
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com
